MARKET

PPBT

PPBT

Purple Biotech Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.080
+0.020
+0.49%
After Hours: 4.120 +0.04 +0.98% 19:28 04/13 EDT
OPEN
4.090
PREV CLOSE
4.060
HIGH
4.130
LOW
3.960
VOLUME
283.81K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
2.790
MARKET CAP
71.44M
P/E (TTM)
-0.0838
1D
5D
1M
3M
1Y
5Y
Purple Biotech Highlights Presentation Of NT219 Mechanism Of Action Data At AACR Annual Meeting
Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune
Benzinga · 17h ago
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional prec...
GlobeNewswire · 17h ago
Top Penny Stocks To Buy Now? 3 Analysts Expect Big Upside From These
Apr 11, 2021 (Penny Stocks via COMTEX) -- Penny Stocks To Buy According To Analysts Whether you love penny stocks or hate them, you can't argue with the fact...
Penny Stocks · 2d ago
Egypt to produce up to 60 mln Sinovac vaccine doses annually- minister
reuters.com · 5d ago
UPDATE 5-Brazil posts record 3,650 new COVID-19 deaths, unveils two homegrown vaccines
reuters.com · 03/26 12:04
Hot Penny Stocks To Watch With Big News This Week
Mar 19, 2021 (Penny Stocks via COMTEX) -- News Headlines Trigger Momentum For These Penny Stocks Are penny stocks on your watch list right now? If not, you...
Penny Stocks · 03/19 13:31
DJ Purple Biotech Launches Phase 1b/2 Study of CM24 With Bristol's Opdivo
Dow Jones · 03/19 12:30
Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb Preliminary Data from First Part of Study Expected to be Available in Second Half of 2021 REHOVOT, Israel, March 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (...
GlobeNewswire · 03/19 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PPBT. Analyze the recent business situations of Purple Biotech Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PPBT stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 1.15M
% Owned: 6.56%
Shares Outstanding: 17.51M
TypeInstitutionsShares
Increased
4
525.93K
New
5
189.19K
Decreased
1
500
Sold Out
2
2.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.14%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Director
John Waymack
Chief Executive Officer/Director
Itzhak Israel
Chief Financial Officer/Director
Simcha Rock
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Hadas Reuveni
Independent Director
Ido Agmon
Non-Executive Director
Alain Zeitoun
Independent Director
Steven Steinberg
Independent Director
Philip Serlin
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
No Data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Webull offers kinds of Purple Biotech Ltd stock information, including NASDAQ:PPBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PPBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PPBT stock methods without spending real money on the virtual paper trading platform.